FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Portfolio Pulse from Vandana Singh
The FDA has approved Bristol Myers Squibb's Augtyro for treating ROS1-positive non-small cell lung cancer. Acquired through a $4.1 billion deal with Turning Point Therapeutics, Augtyro demonstrated a 79% objective response rate in TKI-naïve patients. It enters a competitive market with existing treatments from Roche, Merck, and AstraZeneca. Augtyro will be available in the U.S. in mid-December 2023, and BMY shares closed at $51.57.
November 16, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca could see increased market competition in lung cancer treatments following the FDA's approval of Bristol Myers Squibb's Augtyro.
AstraZeneca, which offers lung cancer treatments, may be affected by the new approved drug Augtyro as it increases the number of options available to patients and physicians, potentially impacting AstraZeneca's sales.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Merck's position in the lung cancer drug market could be challenged by the approval of Bristol Myers Squibb's Augtyro.
Merck, as a key player in the lung cancer treatment market, could experience competitive pressure with the introduction of Augtyro, which may affect its market share and revenue from its own lung cancer drugs.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Roche Holdings may face increased competition in the lung cancer treatment market with the FDA approval of Bristol Myers Squibb's Augtyro.
The entry of Augtyro into the market creates additional competition for Roche's lung cancer treatments. While Roche has an established presence, any new competitor can potentially erode market share and impact sales.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Bristol Myers Squibb's Augtyro has been approved by the FDA for lung cancer treatment, which could boost the company's oncology portfolio and potentially increase its market share in cancer treatments.
FDA approval of a new drug typically leads to positive market sentiment, as it allows the company to generate revenue from the new product. Given the $4.1 billion investment in acquiring Turning Point Therapeutics for this drug, the approval is a significant milestone for Bristol Myers Squibb.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100